PubMed/United States/ 2012/4 |
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome. Gynecologic Oncology1616 Strasberg SM, Linehan DC, Hawkins W. The Accordion Severity Grading System of Surgical Complications. Ann of Surg. [Internet]. 2009 [access on 12 mar 2020]; 250(2): 177-186. Available in: https://insights.ovid.com/crossref?an=00000658-200908000-00001. https://insights.ovid.com/crossref?an=00...
|
To describe the surgical technique, the complications and the results after anterior PE with total vaginectomy (APETV) for recurrent or persistent genitourinary malignancies. |
11/55/APETV: 11 |
Cervical: 6; Uterine: 3; Vaginal: 1 |
648/10 |
Early complication: 3; Late complication: 1. Clavien-Dindo (G3-G4: 4) |
Infection: 4/0 |
PubMed/Brazil/ 2012/4 |
Prognostic factors in pelvic exenteration for gynecological malignancies. EJSO the Journal of Cancer Surgery1717 Minar L, Felsinger M, Rovny I, Zlamal F, Bienertova-Vasku J, Jandakova E. Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases. Acta Obstet Gynecol Scand. [Internet]. 2017 [access on 10 jan 2020]; 96(9): 1136-1143. Available in: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/aogs.13177. https://obgyn.onlinelibrary.wiley.com/do...
|
To analyze morbidity, mortality and prognostic factors after PE. |
107/56.4/TPE: 56; APE: 31; PPE: 10 |
Cervical: 73; Uterine: 17; Vaginal: 10; Vulvar: 7 |
---/0 |
Early complication: 70; Late complication: 58. Only listed |
Infection: 40; Surgical reapproach: 33/0 |
PubMed/United States/ 2012/4 |
The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecologic Oncology1818 Soeda S, Furukawa S, Sato T, Ueda M, Kamo N, Endo Y, et al. Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer. Anticancer Res. [Internet]. 2019 [access on 12 mar 2020]; 39(10): 5631-5637. Available in: https://doi.org/10.21873/anticanres.13759. https://doi.org/10.21873/anticanres.1375...
|
To assess the preoperative Body Mass Index rates, surgical outcomes, and PE complication and/or recurrence rates. |
161/54.4/TPE: 110; APE: 35; PPE: 16 |
Cervical: 86; Uterine: 15; Vaginal: 38; Vulvar: 21 |
568/19 |
Early complication: 210; Late complication: 105. Only listed |
Complication with vaginal reconstruction: 63; Urinary complication: 60/0 |
PubMed/ Belgium/ 2012/4 |
Pelvic exenterations for gynecological malignancies: a study of 36 cases. International Journal of Gynecological Cancer99 Schmidt AM, Imesch P, Fink D, Egger H. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecologic Oncology. [Internet]. 2012 [access on 12 mar 2020]; 125 (3): 604-609. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0090825812001722. https://linkinghub.elsevier.com/retrieve...
|
To assess the surgical outcomes, survival and morbidity associated with PE. |
36/57/TPE: 27; APE: 5; PPE: 3 |
Cervical: 18; Uterine: 9; Ovarian: 1; Vaginal: 8 |
390/25 |
Early complication: 28; Late complication: 18. CTCAE (G1-G2: 12; G3-G4: 27) |
Infection: 18; Urinary complication: 17/0 |
PubMed/ France/ 2012/4 |
Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer. International Journal of Gynecological Cancer88 Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: Método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto contexto- enferm. [Internet]. 2008 [access on 07 feb 2020]; 17(4): 758-764. Available in: http://dx.doi.org/10.1590/S0104-07072008000400018. http://dx.doi.org/10.1590/S0104-07072008...
|
To evaluate the morbidity of modified posterior PE (MPPE) at the time of primary and interval cytoreductive surgeries after neoadjuvant chemotherapy. |
63/58/MPPE: 63 |
Ovarian: 63 |
447/14 |
Clavien-Dindo and MSKCC (G1-G2: 51; G3-G4: 41) |
Infection: 60; Intestinal complication: 9; Rehospitalization: 9/0 |
PubMed/Switzerland/ 2012/4 |
Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecologic Oncology1313 Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Fagotti A, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. International Journal of Gynecological Cancer. [Internet]. 2014 [access on 12 jan 2020]; 24(1): 156-164 (a). Available in: https://ijgc.bmj.com/content/24/1/156. https://ijgc.bmj.com/content/24/1/156...
|
To summarize the PE clinical experience as a treatment for cervical cancer, focusing on the indications and results in patients from specific groups. |
282/50/TPE: 262; APE: 14; PPE: 6 |
Cervical: 282 |
---/--- |
Only listed |
Fistulas: 42; Infection: 20; Anastomosis-related problems: 21/14 |
PubMed/Korea/ 2012/4 |
Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. Journal of Gynecological Oncology1919 Baiocchi G, Guimaraes GC, Oliveira RAR, Kumagai LY, Faloppa CC, Aguiar S, et al. Prognostic factors in pelvic exenteration for gynecological malignancies. EJSO the Journal of Cancer Surgery. [Internet]. 2012 [access on 12 mar 2017]; 38: 948-954. Available in: https://pubmed.ncbi.nlm.nih.gov/22818842/. https://pubmed.ncbi.nlm.nih.gov/22818842...
|
To assess survival and morbidity after PE for the curative treatment of recurrent cervical cancer. |
61/61/TPE: 42; APE: 17; PPE: 2 |
Cervical: 61 |
600/34.3 |
Early complication: 13; Late complication: 25. Only listed |
Fistula: 15; Infection: 6; Intestinal complication: 6; Complication with vaginal reconstruction: 6/0 |
PubMed/Sweden/ 2013/4 |
Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. International Journal of Gynecological Cancer44 Jager L, Nilsson PL, Rådestad AF. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution. International Journal of Gynecological Cancer. [Internet]. 2013 [access on 05 feb 2020]; 23(4): 755-762. Available in: https://ijgc.bmj.com/content/23/4/755. https://ijgc.bmj.com/content/23/4/755...
|
To assess the results in patients subjected to PE surgeries for recurrent gynecological malignancies. |
28/61/TPE: 11; APE: 2; PPE: 15 |
Cervical: 10; Uterine: 4; Ovarian: 5; Vaginal: 5; Vulvar: 1 |
455/22 |
Early complication: 41; Late complication: 24. Clavien-Dindo (G1-G2: 45; G3-G4: 18; G5: 2) |
Infection: 28; Intestinal complication: 4/2 |
PubMed/Thailand/ 2013/4 |
Characteristics of gynecologic oncology patients in King Chulalongkorn Memorial Hospital - complications and outcome of pelvic exenteration. Asian Pacific Journal of Cancer Prevention2020 Berreta R, Marchesi F, Volpi L, Ricotta G, Monica M, Sozzi G, et al. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome. Asia Oceania J Obstet Gynaecol. [Internet]. 2016 [access on 10 jan 2020]; 55 (3): 346-50. Available in: https://www.sciencedirect.com/science/article/pii/S1028455916300328?via%3Dihub. https://www.sciencedirect.com/science/ar...
|
To assess the characteristics of the patients, the surgical procedure, the outcomes and the complications. |
13/52/TPE: 9; APE: 1; PPE: 3 |
Cervical: 5; Ovarian: 7; Vulvar: 1 |
532/35 |
Only listed |
Infection: 8; Fistula: 2/0 |
PubMed/Germany and Italy/ 2014/4 |
Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. International Journal of Gynecological Cancer77 Silva, IA; Carneiro ICRS; Santana ME; Ferreira IP. EXENTERAÇÃO PÉLVICA: Análise de complicações pós-cirúrgicas e óbito hospitalar para construção de cartilha educativa. 2018, 154f. Dissertação (Mestrado em Saúde na Amazônia) - Universidade Federal do Pará, Belém, 2018 [access on 20 dec 2022.] Available in:https://sigaa.ufpa.br/sigaa/public/programa/defesas.jsf?lc=pt_BR&id=1857. https://sigaa.ufpa.br/sigaa/public/progr...
|
To assess postoperative morbidity and mortality in patients subjected to PE for primary or recurrent gynecological malignancies. |
230/54/TPE: 131; APE: 68; PPE: 31 |
Cervical: 177; Uterine: 28; Vaginal: 9; Vulvar: 16 |
446/24 |
MSKCC (G1-G2: 146; G3-G4: 49; G5: 7) |
Infection: 66; Dehiscence: 60/7 |
PubMed/Germany and Italy/ 2014/4 |
Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients. International Journal of Gynecological Cancer2121 Oranratanaphan S, Termrungruanglert W, Sirisabya N. Characteristics of gynecologic oncology patients in King Chulalongkorn Memorial Hospital - complications and outcome of pelvic exenteration. Asian Pacific Journal of Cancer Prevention. [Internet]. 2013 [access on 05 jan 2020]; 14(4): 2529-2532. Available in: http://koreascience.or.kr/article/JAKO201321251181184.page. http://koreascience.or.kr/article/JAKO20...
|
To assess long-term morbidity and mortality and survival in patients subjected to PE with a curative intention for endometrial adenocarcinoma recurrence over a decade. |
21/66/TPE: 10; APE: 6; PPE: 5 |
Uterine: 21 |
382/22 |
Only listed |
Infection: 7; Dehiscence: 5/0 |
PubMed/United States/ 2014 /4 |
Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecologic Oncology1515 Kaur M, Joniau S, D’Hoore A, Van Calster B, Van Limbergen E, Leunen K, et al. Pelvic exenterations for gynecological malignancies: a study of 36 cases. International Journal of Gynecological Cancer. [Internet]. 2012 [access on 12 mar 2020]; 22(5): 889-896. Available in: https://ijgc.bmj.com/content/22/5/889. https://ijgc.bmj.com/content/22/5/889...
|
To assess if preoperative age affects the surgical results, the complication rates and/or recurrence in women subjected to PE. |
161/55/TPE: 103; APE: 35; PPE: 23 |
Cervical: 86; Uterine: 15; Vaginal: 38; Vulvar: 21 |
562/19 |
Early complication: 210; Late complication: 105. Only listed |
Complication with vaginal reconstruction: 63; Urinary complication: 60/0 |
PubMed/United States/ 2014/4 |
Should pelvic exenteration for symptomatic relief in gynaecology malignancies be offered? Archives of Gynecology and Obstetrics2222 Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Gallotta V, et al. Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients. International Journal of Gynecological Cancer. [Internet]. 2014 [access on 05 feb 2020]; 24(5): 880-884 (b). Available in: https://ijgc.bmj.com/content/24/5/880. https://ijgc.bmj.com/content/24/5/880...
|
To review exenterative treatments and surgeries performed with a palliative intention, and to assess their role in relapsed gynecological malignancies. |
18/54/TPE: 9; APE: 5; PPE: 4 |
Cervical: 12; Uterine: 1; Vulvar: 5 |
570/24 |
Transoperative complication: 1: Early complication: 15. Clavien-Dindo (G1-G2: 6; G3-G4: 10) |
Surgical reapproach: 10; Infection: 4/0 |
PubMed/Brazil/ 2014 /4 |
Surgical results of pelvic exenteration in the treatment of gynecologic cancer. World Journal of Surgical Oncology2323 Pathiraja P, Sandhu H, Instone M, Haldar K, Kehoe S. Should pelvic exenteration for symptomatic relief in gynaecology malignancies be offered? Arch Gynecol Obstet. [Internet]. 2014 [access on 12 mar 2020]; 289(3): 657-62. Available in: https://link.springer.com/article/10.1007%2Fs00404-013-3023-5. https://link.springer.com/article/10.100...
|
To assess the PE surgical results and complications in the treatment of gynecologic malignancies and to compare the complications related to the surgery associated with different types of exenteration. |
28/55/TPE: 14; APE: 7; PPE: 7 |
Cervical: 18; Uterine: 3; Ovarian: 6; Vaginal: 1 |
269/9 |
Clavien-Dindo (G1-G2: 6; G3-G4: 6; G5: 4) |
Fistula: 16; Infection: 7; Surgical reapproach: 7/0 |
PubMed/Japan/ 2014 /4 |
Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. International Journal of Clinical Oncology2424 Petruzziello A, Kondo W, Hatschback SB, Guerreiro JA, Penegalli Filho F, Vendrame C, et al. Surgical results of pelvic exenteration in the treatment of gynecologic cancer. World Journal of Surgical Oncology. [Internet]. 2014 [access on 12 mar 2020]; 12: 1-7. Available in: https://wjso.biomedcentral.com/articles/10.1186/1477-7819-12-279. https://wjso.biomedcentral.com/articles/...
|
To evaluate patients subjected to PE and to determine the clinical condition and characteristics associated with the result and survival. |
12/46/TPE: 3; APE: 8; PPE: 1 |
Cervical: 12 |
491/65 |
Only listed |
Infection: 5; Intestinal complication: 5; Complication with vaginal reconstruction: 3/0 |
PubMed/Bolivia /2015/4 |
Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience. International Journal of Gynecological Cancer1414 Revaux A, Rouzier R, Ballester M, Selle, F Darai E, Chéreau E. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer. International Journal of Gynecological Cancer. [Internet]. 2012 [access on 12 mar 2020]; 22(8): 1349-1354. Available in: https://ijgc.bmj.com/content/22/8/1349. https://ijgc.bmj.com/content/22/8/1349...
|
To establish the most favorable cases for PE by reviewing the institutional experience. |
10/54/TPE: 8; APE: 1; PPE: 1 |
Cervical: 3; Uterine: 2; Ovarian: 1; Vaginal: 2; Vulvar: 1 |
545/26 |
Only listed |
Infection: 15; Surgical reapproach: 8; Complication with vaginal reconstruction: 8/1 |
PubMed/Taiwan/ 2016/4 |
Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome. Journal of Obstetrics and Gynaecology2525 Tanaka S, Nagase S, Kaiho-Sakuma M, Nagai T, Kurosawa H, Toyoshima M, et al. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. International Journal of Clinical Oncology. [Internet]. 2014 [access on 12 mar 2020]; 9(1): 133-138. Available in: https://link.springer.com/article/10.1007%2Fs10147-013-0534-9. https://link.springer.com/article/10.100...
|
To evaluate clinical outcomes and postoperative quality of life in patients locally affected by advanced ovarian cancer and subjected to posterior PE with Hudson-Delle Piane radical retrograde hysterectomy. |
22/65/PPE: 22 |
Ovarian: 22 |
520/13 |
Transoperative complication: 14: Early complication: 18. Clavien-Dindo (G1-G2: 15; G3-G4: 21) |
Surgical reapproach: 14; Blood-related complication: 9/0 |
PubMed/ Czech Republic/ 2017/4 |
Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases. Acta Obstetricia et Gynecologica Scandinavica2626 Iglesias DA, Westin SN, Rallapalli V, Huang M, Fellman B, Urbauer, et al. The Effect of Body Mass Index on Surgical Outcomes and Survival Following Pelvic Exenteration. Gynecol Oncol. [Internet]. 2012 [access on 12 mar 2017]; 125(2): 1-15. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850365/. https://www.ncbi.nlm.nih.gov/pmc/article...
|
To investigate the possible benefits of a complete cytoreduction in patients with advanced ovarian cancer and concomitant rectal invasion, as well as the morbidity associated with radical surgery. |
35/61/MPPE: 35 |
Ovarian: 35 |
283/--- |
Early complication: 34; Late complication: 9; Transoperative complication: 10. Clavien-Dindo (G1-G2: 26; G3-G4: 13) |
Blood-related complication: 16; Infection: 14/0 |
PubMed/Argentina/ 2017/4 |
Exenteración pélvica para neoplasias ginecológicas: Complicaciones postoperatorias y resultados oncológicos. Actas Urológicas Españolas2727 Yoo HJ, Lim MC, Seo SS, Kang S, Yoo CW, Kim JY, et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol. [Internet]. 2012 [access on 01 feb 2020]; 23(4): 242-250. Available in: https://ejgo.org/DOIx.php?id=10.3802/jgo.2012.23.4.242. https://ejgo.org/DOIx.php?id=10.3802/jgo...
|
To assess complications, morbidity and oncological results of PE as a treatment for gynecological tumors. |
35/53.8/TPE: 15; APE: 20 |
Cervical: 23; Uterine: 5; Ovarian: 1; Vaginal: 5; Vulvar: 1 |
322/3 |
Early complication: 29; Late complication: 32. Clavien-Dindo (G1-G2: 25; G3-G4: 6) |
Infection: 24; Urinary complication: 15/0 |
PubMed/United States/ 2018/4 |
Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecologic Oncology2828 Romeo A, Gonzalez MI, Jaunarena J, Zubieta ME, Favre G, Tejerizo JC. Exenteración pélvica para neoplasias ginecológicas: complicaciones postoperatorias y resultados oncológicos. Actas Urol Esp. [Internet]. 2017 [access on 10 jan 2020]; 42(2): 121-125. Available in: https://www.sciencedirect.com/science/article/pii/S0210480617301158. https://www.sciencedirect.com/science/ar...
|
To assess the preoperative predictors of severe surgical complications at 30 days. |
138/61.9/TPE: 45; APE: 52; PPE: 41 |
Cervical: 51; Uterine: 38; Vaginal: 18; Vulvar: 21; Others: 10 |
---/--- |
Early complication: 137. Accordion Severity Grading (G1-G2: 100; G3-G4: 37) |
Surgical reapproach: 57; Rehospitalization: 25; Urinary complication: 15/3 |
PubMed/Japan /2019/4 |
Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer2929 Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu WF, Glaser GE, et al. Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecologic Oncology. [Internet]. 2018 [access on 05 jan 2020]; 152(1): 151-156. Available in: https://www.gynecologiconcology-online.net/article/S0090-8258(18)31350-7/fulltext. https://www.gynecologiconcology-online.n...
|
To evaluate PE to determine validity of the evolutions. |
13/53/TPE: 7; APE: 4; PPE: 2 |
Cervical: 8; Uterine: 3; Vaginal: 1; Vulvar: 1. |
625/52.5 |
Clavien-Dindo (G1-G2: 6; G3: 5) |
Infection: 6; Dehiscence: 3; Ileus: 2/0 |
PubMed/Germany /2019/4 |
Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases3030 Gregorio N de, Gregoria A de, Ebner F, Frriedl TWP, Huober J, Hefty R, et al. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet. [Internet]. 2019 [access on 12 mar 2020]; 300(1):161-168. Available in: https://doi.org/10.1007/s00404-019-05154-4. https://doi.org/10.1007/s00404-019-05154...
|
To report the institutional experience in PE of the Obstetrics and Gynecology department at the Ulm University Hospital. |
37/60/TPE: 10; APE: 17; PPE: 6; LEER: 4 |
Cervical: 22; Uterine: 6; Vulvar: 9. |
510/21 |
Only listed |
Infection: 6; Surgical reapproach: 6; Fistula: 5/0 |
PubMed/Italy/2019/4 |
Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature3131 Bizzarri N, Chiantera V, Ercoli A, Fagotti A, Tortorella L, Conte C, et al. Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature. Minim Invasive Gynecol. [Internet]. 2019 [access on 10 jan 2020]; 26(7):1316-1326. Available in: https://doi.org/10.1016/j.jmig.2018.12.019. https://doi.org/10.1016/j.jmig.2018.12.0...
|
To assess the viability and efficacy of Minimally-Invasive PE (MIPE) in a series of multi-institutional Italian cases of women with gynecological cancer and a literature review. |
23/64/TPE: 5; APE: 18 |
Cervical: 10; Uterine: 9; Vaginal: 3; Urothelial: 1 |
540/10 |
Early complication: 10; Late complication: 13. Clavien-Dindo (G1-G2: 1; G3: 6) |
Urinary complication: 6; Infection: 4; Intestinal complication: 3/0 |